Innovative Drugs of Abuse Screening Analyzer Launched in the US

MedTest has announced the commercial launch of urine drugs of abuse screening reagents for the Mindray BA-800M Chemistry Analyzer for use in clinical laboratories in the United States.

The broad urine drugs of abuse screening menu available on the BA-800M meets the three challenges of large volume laboratories performing such testing: efficiency in processing a large number of samples, efficiency in reagent utilization and reduced overall operating costs. A complete chemistry testing menu is also in development for the BA-800M analyzer.

The BA-800M Chemistry Analyzer produces 800 photometric test results per hour with an overall throughput of 1200 tests per hour with ISE. The Sample Delivery Module provides a sample capacity of 440 positions, providing large volume laboratories hours of unmanned operational time. The reagent consumption design of this analyzer minimizes reagent usage per test and reduces the reagent bottle dead volume ensuring that the laboratory is efficiently utilizing the reagents and providing the lowest consumption cost per test. Advanced features of the BA- 800M Analyzer offer processing efficiencies such as continuous reagent loading, Reagent Bubble Detection, Water Quality Monitor, One-Key STAT Touch button, Probe Liquid Level and Clot Detection, and Collision Recovery which provides the laboratory with smooth operational and enhanced workflow efficiencies. A unique capability is that the BA-800M can be twinned to double the operating and throughput capacity for those labs that need to grow their testing capability.

Hanjoon Ryu, CEO of MedTest, stated: “MedTest is privileged to introduce this model, designed for the large-volume laboratory, to the US market. Adding the BA-800M to our instrument portfolio of the BS-200 and the BS-480 enhances our testing solutions across the board from small volume labs to very large volume labs. Being able to twin the BA-800M analyzer provides the laboratory with confidence that they can double their testing volume without having to adopt a new testing system and all of the corresponding validation work associated with a new system.”